Enliven Therapeutics ELVN Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's retained earnings?
- Enliven Therapeutics (ELVN) reported retained earnings of -$370.79M in Q1 2026.
- How has Enliven Therapeutics's retained earnings changed year-over-year?
- Enliven Therapeutics's retained earnings decreased by 36.3% year-over-year, from -$272.02M to -$370.79M.
- What is the long-term trend for Enliven Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Enliven Therapeutics's retained earnings has grown at a 29.3% compound annual growth rate (CAGR), from -$96.11M to -$347.17M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.